Know Labs Announces Bio-RFID Product Platform
Measuring more than Blood Glucose
Seattle, WA. — October 11, 2018 — Know Labs, Inc. (OTCQB: KNWN) — a provider of diagnostic solutions, released today a video highlighting the Company’s product pathway and platform. In the video CEO Phil Bosua discusses the Company’s Bio-RFID™ technological breakthrough and the plans for bringing the technology to market.
The transcript of Phil Bosua’s narrative in the video states in part:
“We originally set out to detect blood glucose and in turn, created a platform. We’ve begun initial research to measure all types of substances in the blood and interstitial fluid. Biomarkers like cortisol for stress levels, as well as continuous measurement of the luteinizing hormone, which would indicate ovulation within the next 4 hours — ideal for those wanting to get pregnant. We’re now ahead of schedule and look forward to creating the future of non-invasive health measurements.”
About Visualant, Inc.
VisualantTM is a public company whose shares trade under the stock symbol “VSUL.” The Visualant technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaIDTM and Bio-RFIDTM. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Visualant, visit the company’s website at www.visualant.net.
Contact:
Name: Jordyn Theisen
Phone: 319–321–8470
Email: Jordyn@knowlabs.co
Link to Original Press Release: https://www.businesswire.com/news/home/20181011005241/en/Labs-Announces-Bio-RFID%E2%84%A2-Product-Platform
